AI tools seen shortening drug development timelines and raising pharma profits

Artificial intelligence is accelerating drug development and lowering costs across the pharmaceutical industry, potentially boosting operating profits by more than 10%. AI tools are increasingly being adopted across the clinical development process, helping pharmaceutical companies design trials more efficiently, recruit patients faster, and automate regulatory submissions. These improvements could shorten drug development timelines by roughly 18 months while also lowering research and development spending by about 5% over the next several years.

Developing a new medicine is traditionally a lengthy and expensive process, often taking more than a decade and requiring significant investment before a product reaches the market. Much of the time and cost occurs during clinical trials and regulatory review, where companies must recruit patients, manage large volumes of data, and prepare detailed regulatory filings. AI is increasingly being used to streamline these stages by analyzing historical trial data, improving protocol design, optimizing clinical site selection, and enhancing patient monitoring during trials.

These efficiencies can help reduce delays, limit costly amendments to trial protocols, and speed up regulatory documentation. Faster development timelines could also extend the period during which drugs generate revenue before patents expire and generic competition emerges. Earlier market entry, combined with lower R&D costs, could translate into a significant improvement in profitability for major pharmaceutical companies.

Life sciences companies are racing to deliver on an AI promise: faster identification of promising therapies, streamlined development, and novel treatments reaching patients sooner and safer. Biotechs and pharma companies are integrating the latest generative AI models into their R&D systems: analyzing vast volumes of data, identifying patterns to inform recommendations or predictions, and optimizing clinical studies. The shape of these partnership arrangements is beginning to resemble a pure AI licensing model, with pharma companies now prioritizing the ability to take third-party model weights and fine-tune them using proprietary datasets on their own infrastructure.

However, realizing these benefits depends on the quality and provenance of the data that feeds them. Depending on the model, this may include clinical trial data, real-world evidence, genomic data, electronic health records, and publicly available datasets. If this data is not traceable, accountable, and compliant, it can introduce privacy and legal risk.

Another concern is secondary use, where AI models are trained on data collected from trials conducted before the technology existed, meaning the patient could not have explicitly consented to such use. This raises questions about whether original consent frameworks adequately cover the application of personal health data to train machine learning algorithms, particularly when those models may be commercialized or used in ways that were not contemplated at the time of data collection. For companies on both sides of AI-pharma deals, rigorous data provenance practices are becoming essential to managing risk and ensuring long-term value.

Large pharmaceutical companies with global clinical development capabilities are expected to benefit the most from the shift, as they have the scale, data, and infrastructure needed to deploy AI effectively. Companies highlighted as among those well positioned to capture the upside from AI-driven efficiencies include Daiichi Sankyo, Takeda, and Astellas. AI is expected to improve productivity across the industry, but drug development will remain capital-intensive and heavily regulated.